about
Blockade of XBP1 splicing by inhibition of IRE1α is a promising therapeutic option in multiple myelomaA novel vascular disrupting agent plinabulin triggers JNK-mediated apoptosis and inhibits angiogenesis in multiple myeloma cellsClinical and translational studies of a phase II trial of the novel oral Akt inhibitor perifosine in relapsed or relapsed/refractory Waldenstrom's macroglobulinemiaHonokiol overcomes conventional drug resistance in human multiple myeloma by induction of caspase-dependent and -independent apoptosisAzaspirane (N-N-diethyl-8,8-dipropyl-2-azaspiro [4.5] decane-2-propanamine) inhibits human multiple myeloma cell growth in the bone marrow milieu in vitro and in vivoAmerican Society of Blood and Marrow Transplantation, European Society of Blood and Marrow Transplantation, Blood and Marrow Transplant Clinical Trials Network, and International Myeloma Working Group Consensus Conference on Salvage Hematopoietic CeA review of second primary malignancy in patients with relapsed or refractory multiple myeloma treated with lenalidomideInternational Myeloma Working Group consensus statement for the management, treatment, and supportive care of patients with myeloma not eligible for standard autologous stem-cell transplantationBET bromodomain inhibition as a therapeutic strategy to target c-MycTargeting CD38 with Daratumumab Monotherapy in Multiple MyelomaDual inhibition of canonical and noncanonical NF-κB pathways demonstrates significant antitumor activities in multiple myelomaCompartment-Specific Bioluminescence Imaging platform for the high-throughput evaluation of antitumor immune functionA novel small molecule inhibitor of deubiquitylating enzyme USP14 and UCHL5 induces apoptosis in multiple myeloma and overcomes bortezomib resistanceMicroenvironmental influence on pre-clinical activity of polo-like kinase inhibition in multiple myeloma: implications for clinical translationElevated IL-17 produced by TH17 cells promotes myeloma cell growth and inhibits immune function in multiple myelomaFunctional interaction of plasmacytoid dendritic cells with multiple myeloma cells: a therapeutic target.Preclinical data and early clinical experience supporting the use of histone deacetylase inhibitors in multiple myeloma.Second primary malignancies with lenalidomide therapy for newly diagnosed myeloma: a meta-analysis of individual patient data.Defibrotide for Treatment of Severe Veno-Occlusive Disease in Pediatrics and Adults: An Exploratory Analysis Using Data from the Center for International Blood and Marrow Transplant Research.Ricolinostat plus lenalidomide, and dexamethasone in relapsed or refractory multiple myeloma: a multicentre phase 1b trial.Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma.A phase 2 study of bortezomib in relapsed, refractory myeloma.Risk factors and kinetics of thrombocytopenia associated with bortezomib for relapsed, refractory multiple myeloma.Safety of prolonged therapy with bortezomib in relapsed or refractory multiple myeloma.Bortezomib in combination with dexamethasone for the treatment of patients with relapsed and/or refractory multiple myeloma with less than optimal response to bortezomib alone.Optimizing the efficacy and safety of bortezomib in relapsed multiple myeloma.Diagnostic criteria for hematopoietic stem cell transplant-associated microangiopathy: results of a consensus process by an International Working Group.Safety and efficacy of bortezomib in high-risk and elderly patients with relapsed multiple myeloma.Characterisation of haematological profiles and low risk of thromboembolic events with bortezomib in patients with relapsed multiple myeloma.Safety and efficacy of single-agent lenalidomide in patients with relapsed and refractory multiple myeloma.Multicenter, phase I, dose-escalation trial of lenalidomide plus bortezomib for relapsed and relapsed/refractory multiple myeloma.Melphalan, prednisone, thalidomide and defibrotide in relapsed/refractory multiple myeloma: results of a multicenter phase I/II trial.Phase II trial of weekly bortezomib in combination with rituximab in relapsed or relapsed and refractory Waldenstrom macroglobulinemiaLenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma.Phase II clinical and pharmacokinetic study of plitidepsin 3-hour infusion every two weeks alone or with dexamethasone in relapsed and refractory multiple myeloma.Phase II trial of weekly bortezomib in combination with rituximab in untreated patients with Waldenström Macroglobulinemia.Weekly bortezomib in combination with temsirolimus in relapsed or relapsed and refractory multiple myeloma: a multicentre, phase 1/2, open-label, dose-escalation study.A phase I safety study of enzastaurin plus bortezomib in the treatment of relapsed or refractory multiple myeloma.Perifosine plus lenalidomide and dexamethasone in relapsed and relapsed/refractory multiple myeloma: a Phase I Multiple Myeloma Research Consortium study.How I treat plasma cell leukemia.
P50
Q24598483-600FA806-5EC6-43E6-B11E-7EB8794DF99CQ24622083-951DE529-F5AB-4004-9EF9-4EA526BAAD7FQ24634360-518D4B7B-7D70-48B1-87AE-C483CBBD9412Q24669763-DFDACC98-E86C-4D69-9995-5D0DACDE5182Q24670297-890B3A31-683D-4B41-A28D-2105851C5879Q26782868-8DE88970-2DD4-4EF9-B7B4-EA8CBB0FE90DQ26865089-AF79E02C-AEEE-427B-B59D-F97914FEBBAFQ27002668-93F5EADC-E080-4776-941B-AE73B6ECA576Q28247024-99DFBEBE-4E64-4C23-97C5-AA441677ECCCQ28266655-210382BF-C7A7-4CC8-B5BC-9DBEFCFA055EQ28271286-734B6483-7093-40DF-B8AE-F4A8B0E7502DQ28383385-FC1347DA-FD21-4EBA-8775-8D9151401C4DQ28395203-2B485564-8AD7-49CE-B385-08523024EA14Q28478937-1F70B891-8BC1-40A2-9300-662B0D28BF66Q30431530-436B8231-2A78-4A67-9379-ED987C67418BQ30490975-FA40D61A-6C75-4587-8EE1-7757D0D5B5BDQ30615908-AFFD71EC-1ABC-4626-9056-52AC1C95C770Q30756778-91A6DCD7-45AD-4DD0-9E5E-6B3F40D99EB4Q31083746-9DFC0ACF-A5AC-4153-A364-ED69B7D9CF21Q33167710-140B7D35-EEDA-477A-9701-D4474485745BQ33344746-085B637D-F613-4BA9-9F2E-1B7861034A8BQ33348702-E78844F9-1148-40C0-A230-46A9B9FD5F7BQ33367821-92ED587B-E103-42AC-B3C9-DBFC66FEDABCQ33368803-C4A3FE93-6543-4F8A-981D-09791A3A6AE2Q33371830-8F6BE908-BB6A-4D33-AF7A-E238F0BCA5E4Q33371892-51F0DE80-B726-4269-BE5D-CB7C963FECF0Q33373889-9E3D5081-5722-432F-A523-B75EA5EE384DQ33374964-96187199-A2A6-4AE9-8D38-31F426230EE4Q33380816-102B2B9B-947F-4783-9576-E763D3BD554DQ33384668-A2D0397E-2DAF-42B0-98F9-56E14AD8C36EQ33386405-E6FE9E0E-A77E-4A4A-B95E-CFF12D045771Q33387733-824BC4FA-E808-47C8-AA4C-FF1E9089D4A5Q33388196-41D95FCC-2125-43BD-9822-443DB60DAF82Q33389111-5F8AAE27-0546-41A6-9BC9-1E6D1DDCA5E9Q33389982-8C436992-29F4-41C8-BA70-6E648D2EAEDBQ33390926-3C4ECAC1-A879-4B73-A088-C7C572974F60Q33394281-592B81C5-7A41-444D-8363-4ED0176162DEQ33395607-0DDF636B-4D71-47D7-A2E2-372BCD07EF77Q33401457-38B5FA6B-DC0E-458C-ACD8-38A33058BFB0Q33402555-789FD853-9495-4DF7-AE39-1849EDFEA694
P50
description
investigador
@es
researcher
@en
wetenschapper
@nl
name
Paul G Richardson
@en
Paul G Richardson
@nl
type
label
Paul G Richardson
@en
Paul G Richardson
@nl
prefLabel
Paul G Richardson
@en
Paul G Richardson
@nl
P31
P496
0000-0002-7426-8865